Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Raises Price Target to $110

Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on CRISPR Therapeutics (NASDAQ: CRSP) and raised the price target from $105 to $110. This adjustment reflects a positive outlook on the company's performance.